finance

Dialysis drug pioneer Invizius appoints four high-profile directors



The University of Edinburgh spin-out developing a treatment that could save the lives of dialysis patients has appointed a chairman and made three other significant board appointments.

Eric Beard joins Invizius as chairman, having been a vice president of Baxter Healthcare and president of its global renal dialysis business. He has held senior positions at Sorin Group and Gish Biomedical, both active in the renal and oxygenation markets, and as executive chairman at Cellnovo.

Zurich-based Dr Sandra Neumann, a former general manager of Baxter’s renal business, joins as non-executive director. She is founder and CEO of Peripal, which is developing a patient aid for dialysis, a board member at Solvias and a former senior associate at McKinsey & Company.

Dr Magnus Nicolson is appointed chief operating officer, having led companies including Viragen, CytoKine PharmaSciences and EctoPharma. He was general manager of the BASF Pharma plant on Lewis and is chair of SRSL at the Scottish Association for Marine Science.

James Robson becomes chief financial officer, having worked in the Boots and Reckitt Benckiser groups and, more recently, headed the European arm of Japanese pharma company Shionogi. He is CFO of University of Warwick spin-out Medherant.

The new directors’ arrival follows the recent £2.75 million investment in October by investors including Mercia, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank.

Invizius’s H-Guard is a powerful anti-inflammatory that could reduce the death toll from cardiovascular disease among long-term dialysis patients. The company is preparing to enter clinical trials and aims to raise Series A funding within 18 months.

Read More   How sticking plasters became a million dollar idea

Richard Boyd, co-founder and CEO of Invizius, said: “We are delighted to welcome such high-calibre individuals to our team. Their experience will be invaluable in guiding the business through the next stage of its development as we move closer towards our goal to improve the lives of three million dialysis patients.”

Dr Nicola Broughton of Mercia said: “Invizius’ success in attracting these internationally renowned industry figures demonstrates the respect in which it is held and their confidence in its technology. The new line-up makes the company well placed to become a global success story.”



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.